Karaboyun, KubilayYolcu, Ahmet2024-10-292024-10-2920232458-9179https://doi.org/10.30569/adiyamansaglik.1355856https://search.trdizin.gov.tr/tr/yayin/detay/1231561https://hdl.handle.net/20.500.11776/13041Aim: We aimed to determine the efficacy and prognostic factors of Regorafenib in advanced colorectal cancer patients. Materials and Methods: This study was designed as single-center and retrospective. The study included 72 patients with metastatic colorectal cancer treated with Regorafenib. Univariate and multivariate analyses of factors affecting survival were generated by Cox Regression Models. Results: Twenty-three (31.9%) of the patients were female, the median age was 65 years. The median progression-free survival (PFS) and overall survival (OS) were 4.13 and 8.7 months, respectively. The carcinoembryonic antigen (CEA) level (p=0.001), and Eastern Cooperative Oncology Group (ECOG) score (p<0.001) were found to be prognostic in the multivariate model for PFS. ECOG (p<0.001), CEA level (p<0.001), dose reduction (p=0.003), and side of the primary tumor (p=0.037) were prognostic for OS. Conclusion: Our study revealed that ECOG, requiring dose reduction during the treatment, and lower baseline CEA levels were found to be prognostic.en10.30569/adiyamansaglik.1355856info:eu-repo/semantics/openAccessSurvivalRegorafenibAdvanced colorectal cancerArticle931992051231561